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ABSTRACT: Many immune-mediated diseases are associated with partic-
ular MHC class I or class II alleles. In rheumatoid arthritis (RA-shared),
the vast majority of patients possess HLA-DRB1 alleles encoding a shared
epitope, which is a five–amino acid sequence motif in positions 70–74
of the HLA-DR chain. The mechanistic basis for this association is
unknown. Here we discuss recent evidence suggesting that the shared
epitope may act as an allele-specific ligand that triggers increased nitric
oxide (NO) production in opposite cells with resultant immune dysregula-
tion. We propose that by doing that, the RA-shared shared epitope may
form an unintended bridge between the innate and adaptive immune
systems, thereby allowing aberrant signaling events that could trigger
disease.
KEYWORDS: autoimmunity; MHC–disease association; signal trans-
duction
INTRODUCTION
Genetic associations with particular class I and class II major histocompat-
ibility complex (MHC) alleles have been observed in many immune-mediated
diseases.1 On the basis of the known role of MHC gene products in antigen
presentation, it has been postulated that the mechanism of these associations
involves T cell repertoire selection and/or recognition of specific antigens. Ev-
idence to support this paradigm exists in some diseases, but in other cases the
basis of MHC–disease association does not appear to involve antigen presenta-
tion. For example, approximately 90% of patients with narcolepsy express the
DQB1∗0602 allele,2 yet to this date, no conclusive evidence for an immune-
based mechanism has been established in this sleep disorder. Instead, recent
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studies suggest that signaling aberrations in the orexin-activated pathway may
be involved.3 Similarly, in hereditary hemochromatosis, an association with
HLA-A3 has been known for decades.4 More recently, however, the association
was found to be due to linkage disequilibrium with a point mutation in HFE,
an adjacent class I HLA-related gene. The mutant HFE protein does not allow
proper transferrin receptor-mediated signaling, with resultant iron overload.5
Thus, in at least two HLA-associated diseases, the etiopathogenesis involves
signaling aberrations rather than antigen presentation. Below, we discuss ev-
idence suggesting that HLA-disease association in rheumatoid arthritis (RA)
may also be attributed to aberrant signaling.
THE RA SHARED EPITOPE: UNANSWERED QUESTIONS
Rheumatoid arthritis (RA) is one of the most prevalent HLA-associated dis-
eases. Its association with HLA-DR4 was noticed three decades ago.6 More
recently, it has been found that the vast majority of RA patients possess HLA-
DRB1 alleles encoding a “shared epitope” (SE), consisted of QKRAA, QR-
RAA, or RRRAA sequences in residues 70–74 of the DR chain.7 Immuno-
genetic analyses8 have demonstrated that among the five SE amino acids,
residues 70, 71, and 74 are critically important, while the identities of residues
72 and 73 do not seem to matter. Thus, a (Q/R)-(K/R)-x-x-A consensus mo-
tif (glutamine or arginine in position 70, lysine or arginine in position 71,
and alanine in position 74) has been proposed as essential and sufficient to
confer RA susceptibility. Further analyses have demonstrated that the nature
of residue 70 is critical for both susceptibility to and protection against RA.
While HLA-DRB1 alleles encoding glutamine or arginine in position 70 are
associated with increased RA susceptibility, alleles encoding aspartic acid in
that position confer protection against the disease.9–11
The mechanism by which the SE affects disease susceptibility is unknown.
Several hypotheses have been proposed, including presentation of arthrito-
genic self-peptides,1 molecular mimicry with foreign antigens,12 or T cell
repertoire selection.13 While these hypotheses are all plausible, they are dif-
ficult to reconcile with the fact that data supporting antigen-specific immune
responses as the primary event in RA are equivocal. Furthermore, SE–disease
association is not unique to RA, as several other human diseases have also
been shown to be associated with SE-encoding DRB1 alleles.14–17 Addition-
ally, the SE has also been shown to confer disease susceptibility in other
species. For example, an association with SE-expressing MHC class II al-
leles has been reported in spontaneous RA-like disease in dogs,18 and trans-
genic mice carrying SE-encoding HLA-DRB1 alleles have been found to have
more severe collagen-induced arthritis19 and experimental encephalomyeli-
tis.20 Thus, the promiscuous association of the SE with pathogenically diverse
diseases, with no apparent antigen- or species-specificity, suggests that in
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addition to its role in antigen presentation, the SE may have antigen nonspecific
effects.
Another feature of RA–SE association, which is difficult to attribute to anti-
gen presentation, is the fact that SE influence in RA is not limited to disease
susceptibility. Several groups have demonstrated correlations between the SE
and disease severity.21 According to those studies, RA in SE-positive individ-
uals, in particular those possessing two SE-encoding HLA-DRB1 alleles, is
more severe, involves more erosions, and starts at an earlier age than RA in
individuals who are SE-negative.21 Furthermore, the SE appears to affect pene-
trance as well. As discussed below, the concordance rate of RA in monozygotic
(MZ) twins is very low.22,23 Quite interestingly, however, the concordance rate
directly correlates with the SE gene dose. While in SE-negative MZ twins the
concordance rate is only 5%, in twins with one SE-encoding HLA-DRB1 allele
it is 13%, and in MZ with two alleles, RA concordance rate reaches 27%.24
Additionally, life table analyses revealed that the probability of RA discordant
twin pairs to become concordant over time correlates with the number of SE-
encoding HLA-DRB1 alleles, with the shortest time to concordance in twins
possessing two such alleles.24
Thus, the lack of evidence to support an antigen-specific immune response,
the promiscuous association of the SE with other diseases, and SE effect on RA
severity and penetrance, all argue against antigen presentation function as the
sole basis of RA–SE association. An alternative hypothesis has been therefore
proposed that, rather than emanating from the antigen presentation function of
the HLA-DR molecule, the RA–SE association is a result of linkage disequi-
librium with another gene. According to this hypothesis, the SE is a surrogate
marker for another gene, such as TNF-,25 which is the actual culprit. Linkage
disequilibrium has been convincingly implicated in another MHC-associated
disease, hereditary hemochromatosis.5 In RA, however, this mechanism ap-
pears to be less likely, since it fails to explain the seemingly random occurrence
of RA among genetically susceptible individuals, best illustrated by the very
low concordance rate of RA in MZ twins.
It has long been observed that despite the strong influence of genetic factors
in RA, the concordance rate of the disease in MZ twins is only 12–15%.22,23
This surprisingly low penetrance contrasts with concordance rates reported in
other autoimmune diseases, such as systemic lupus erythematosus or ankylos-
ing spondylitis,26 and suggests that environmentally driven stochastic (random)
events may be responsible for triggering disease onset in RA. Consistent with
this hypothesis, there are many indications of increased incidence of stochas-
tically occurring molecular events in RA, including protein and lipid damage,
accelerated telomere shortening, DNA damage, and somatic mutations.27–30
The impact of aging on RA incidence and evidence of accelerated immune
senescence in this disease31 lend further support to the theory that stochastically
occurring events may be involved in RA. Epidemiological surveys indicate that
advancing age is a strong risk factor for developing RA. The incidence of the
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disease continuously increases with age and peaks in the eighth decade of life.
Such age-associated increasing susceptibility argues against presentation of
specific antigens, since adaptive immune responses are expected to decline
with age.31
A common denominator to cellular aging and stochastic events is that they
are both associated with oxidative stress, a factor that has long been implicated
in RA pathogenesis.32 Thus, a conceivable unifying explanation could be that
the SE may lead to disease onset by conducing to a pro-oxidative milieu,
which in turn increases the risk of deleterious stochastic events. Consistent
with this model, a significant interaction between the SE and smoking, a well-
known pro-oxidant stressor,33 has been recently reported.34 Padyukov et al.
have found that in SE-positive smokers the relative risk for RA was 7, while
in SE-negative smokers it was 2.4, and a relative risk of 2.8 was found in
SE-positive individuals without a history of smoking. Importantly, smokers
carrying two copies of the SE were found to have a relative risk of 15.7.34
NITRIC OXIDE (NO) SIGNALING TRIGGERED BY THE SE
As discussed above, there is no convincing evidence to support an adaptive
immunity role for the SE in RA. Could the SE possess as yet unknown innate
immunity functions? As a first step to address this question, we have undertaken
to examine the effect of the SE on NO signaling.35
NO is a ubiquitous signaling molecule with versatile roles in the immune
system. Its proinflammatory effects have been noted in RA,36 where increased
NO levels correlate significantly with inflammatory markers of the disease37
and antirheumatic agents have been shown to suppress NO production.36,38 In
addition, excessive NO levels, either alone, or in conjunction with intercurrent
oxidative challenges, can cause mutations,39 increase the risk of lymphoma,40
and accelerate telomere shortening41—events that have all been noted to as-
sociate with RA.27–30 Thus, several lines of evidence suggest that NO may be
an important factor in RA and in its association with the SE.
Our recent data indicate that the SE acts as a ligand, which triggers NO signal-
ing in opposite cells.35 For example, SE-positive B lymphocyte lines exhibited
much higher rates of spontaneous NO production compared to SE-negative
lines. There were no significant differences between SE-positive healthy in-
dividuals and SE-positive RA patients or between SE-positive RA MZ twins
and their healthy co-twins, suggesting that spontaneous NO overproduction is
a SE- rather than RA-associated aberration.
Studies involving L cell transfectants indicate that NO overproduction in
SE-positive cells is contributed by the DRB1 gene itself, rather than by another
gene secondary to linkage disequilibrium. Transfectants expressing on their
surface a SE-positive HLA-DR chain encoded by allele DRB1∗0401 showed
a much higher spontaneous NO production rate compared to transfectants
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expressing on their surface a SE-negative HLA-DR chain encoded by allele
DRB1∗0402.35
The HLA-DR molecule is directly involved in NO signaling, as indicated
by experiments using tetrameric HLA-DR molecules and multimeric protein
particles engineered to express multiple copies of the SE. Class II MHC-
negative fibroblasts stimulated with the SE-positive T-DRB1∗0401 tetramer
generated much higher NO levels, compared to cells stimulated with the con-
trol, SE-negative T-DRB1∗1501 tetramer. The SE-positive tetramer was found
to be a highly specific and potent stimulator of NO production, with an EC50
of ∼3.0 × 10−8 M.35 To further map the active site on SE-expressing proteins,
we genetically engineered the third allelic hypervariable region (HV3, residues
65–79) encoded by SE-positive or SE-negative DRB1 alleles into the spikes
of a recombinant hepatitis B core (HBc) protein capsid, which form  heli-
cal structures, mimicking the native conformation of the HV3. Stimulation of
class II-negative cells with SE-positive HBc chimeric capsids, but not with the
SE-negative capsids, triggered rapid NO production.35 Since the HV3 encoded
by the two alleles differs by only three amino acid residues within the HV3
region, these data map the active site to that region. These results also indicate
that NO signaling can be triggered by “naked” SE-expressing -helical loops,
independent of any antigenic groove peptide.
Activation of NO signals could also be triggered by soluble 15mer synthetic
peptides corresponding to the HV3 of the SE-positive DRB1 allele and when
immobilized on a solid phase could trigger NO signaling within 15–30 min.
SE-triggered NO signaling could be seen in a wide variety of human and murine
cell lineages and involved rapid activation of NO synthase (NOS), followed
by increased levels of cGMP.35
NO is a pleiotropic signaling molecule. Among many other effects, it
has been previously shown to inhibit apoptotic target killing by cytotoxic
T cells.42,43 Since impaired apoptotic elimination of autoreactive cells has
been proposed as a triggering event in RA,44,45 we investigated whether the
SE might be a contributing factor. Our data indicate that SE-positive target
cells are much more resistant to apoptotic killing by cytolytic  T cells. The
resistance could be reversed by preincubation with a NOS inhibitor, indicating
that the resistance was due to NO overproduction.35
A PROPOSED MODEL
Our data indicate that the SE acts as an allele-specific ligand that triggers
NO-mediated signaling events. This pathway is constitutively active in B cells
carrying SE-positive DRB1 alleles and in class II-negative cells transfected
with SE-encoding DRB1 cDNA. The pathway can also be activated by recom-
binant proteins engineered to express the SE ligand in its natural conformation
and by short synthetic peptides expressing the SE motif.
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In its native conformation, the SE occupies approximately 1.5 -helical
loops in the DR1 domain and builds the lateral wall of the fourth pocket of the
peptide-binding groove. It is therefore legitimate to wonder whether interaction
between the SE and a putative receptor on opposite cells is spatially possible.
It should be remembered, however, that the SE is part of the “sidewall” of
the peptide groove, but it is not playing a major role in peptide anchoring, a
function that is mediated primarily by groove “floor” residues. Among the five
amino acid residues of the SE, only one (K/R71) has been shown to interact
with some groove peptides. The other residues interact with outside molecules,
such as the T cell receptor, and/or merely help maintaining the SE -helical
conformation. Additionally, X-ray crystallography studies46 have shown that
the 70–74 region forms a free protrusion, which allows a sizable gap between
the collective electron densities of antigenic peptides and the van der Waals
surface at the region 70–74 of the DR chain. Thus, the SE represents a
relatively free subdomain, which, depending on the level of antigenic peptide
occupancy and the nature of that peptide, could allow sufficient room for
interaction with other molecules.
We propose that the SE may act as a receptor-binding ligand that trig-
gers innate signaling events in opposite cells, analogous to signaling ef-
fects mediated by particular -helical loops in the class I MHC 2 domain
(which closely resemble spatially the DR1 domain). It is well established
that distinct loops in the class I MHC 2 domain bind to cell-surface re-
ceptors, such as killer immunoglobulin-like receptors (KIR), NKG2/CD94
receptors, the transferrin receptor, or the pheromone receptor V2R, and ac-
tivate signal transduction events through these receptors.47–50 Thus, there is
ample evidence that MHC -helical loops can function as receptor-binding
ligands.
FIGURE 1 depicts a proposed model of SE-triggered signaling. According to
this model, the SE ligand interacts with a putative cell-surface receptor and
activates NOS, which in turn activates a cGMP-dependent kinase. We propose
that the consequences of SE-triggered signaling could be dual: (1) Overproduc-
tion of NO could contribute to RA pathogenesis through its proinflammatory
and immune modulation effects. Increased NO levels could also lead to T cell
hyporesponsiveness and resistance to apoptosis,51 two aberrations previously
noted in RA.44,52 (2) Chronic overproduction of NO, perhaps in conjunction
with recurrent daily oxidative stresses, could increase the likelihood of stochas-
tic, disease-initiating events.
We believe this model provides plausible explanations for many of the unan-
swered questions surrounding the role of the SE in RA. For example, SE-
triggered, antigen-independent NO signaling could better explain the lack of
evidence for an antigen-specific immune response in RA on the one hand and
the promiscuous association of SE-expressing alleles with other diseases on
the other. A signaling-based mechanism could also provide a better explana-
tion for the association of the SE with disease severity and its gene–dose effect.
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FIGURE 1. A proposed model of SE-triggered signaling aberration. SE-positive HLA-
DR surface molecules interact in trans with a putative receptor on opposite cells and activate
NOS with resultant activation of a NO-cGMP-PKG signaling cascade. The aberrantly ac-
tivated pathway can lead to several functional consequences, including delayed apoptotic
elimination of lymphocytes, immune dysregulation, and increased susceptibility to oxida-
tive stresses. These aberrations, in turn, could allow the emergence of autoreactive immune
cells, with resultant RA or other SE-associated diseases, depending on the genetic back-
ground of the individual.
Additionally, as a result of the pro-oxidative effects of NO53 the SE could con-
ceivably increase the likelihood of deleterious stochastic events, which could
explain the seemingly random occurrence of RA in genetically susceptible
individuals, the SE effect on penetrance, the association of the disease with
advancing age, and the increased incidence of somatic mutations and prema-
ture telomere attrition observed in RA.
Obviously, many questions remain unanswered. Prominent among them is
the fact that up to 10% of all RA patients do not carry any SE-encoding DRB1
allele. Therefore, the possibility that disease-inducing NO signaling could also
be triggered by SE-independent mechanisms deserves consideration. It should
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be also clarified that the paradigm proposed here and the prevailing adaptive
immunity-based theories are not mutually exclusive. It is conceivable that
while presentation of a putative arthritogenic antigen by the SE is required to
initiate an immune response, the pathogenic consequences of that response are
determined by the unique ability of the SE to co-trigger NO-mediated innate
immunity signals.
ACKNOWLEDGMENTS
J.H. was supported by Grants AI47331, AR46468, and AR20557 from the
U.S. National Institutes of Health; an Innovative Research Grant from the
Arthritis Foundation; and the University of Michigan Biotechnology Devel-
opment Fund. We thank Dr. Mongshang Lin, Dr. Paul Pumpens, Dr. Olga
Borscukova, and Ms. Angela Lai for their expert technical assistance and ad-
vice.
REFERENCES
1. WUCHERPFENNIG, K.W. & J.L. STROMINGER. 1995. Selective binding of self pep-
tides to disease-associated major histocompatibility complex (MHC) molecules:
a mechanism for MHC-linked susceptibility to human autoimmune diseases.
J. Exp. Med. 181: 1597–1601.
2. MIGNOT, E. 1998. Genetic and familial aspects of narcolepsy. Neurology 50: S16–
S22.
3. DAUVILLIERS, Y. & M. TAFTI. 2006. Molecular genetics and treatment of narcolepsy.
Ann. Med. 38: 252–262.
4. SIMON, M., M. BOUREL, R. FAUCHET & B. GENETET. 1976. Association of HLA-A3
and HLA-B14 antigens with idiopathic hemochromatosis. Gut 17: 332–334.
5. CARDOSO, C.S. & M. DE SOUSA. 2003. HFE, the MHC and hemochromatosis:
paradigm for an extended function for MHC class I. Tissue Antigens 61: 263–
275.
6. STASTNY, P. 1976. Mixed lymphocyte cultures in rheumatoid arthritis. J. Clin.
Invest. 57: 1148–1157.
7. GREGERSEN, P.K., J. SILVER & R.J. WINCHESTER. 1987. The shared epitope hypoth-
esis: an approach to understanding the molecular genetics of susceptibility to
rheumatoid arthritis. Arthritis Rhem. 30: 1205–1213.
8. OU, D., L.A. MITCHELL & A.J. TINGLE. 1998. A new categorization of HLA DR
alleles on a functional basis. Hum. Immunol. 59: 665–676.
9. GOURRAUD, P.A., J.F. BOYER, T. BARNETCHE, et al. 2006. A new classification of
HLA-DRB1 alleles differentiates predisposing and protective alleles for rheuma-
toid arthritis structural severity. Arthritis Rheum. 54: 593–599.
10. VAN DER HELM-VAN MIL, A.H.M., T.W.J. HUIZINGA, G.M.T. SCHREUDER, et al.
2005. An independent role of protective HLA class II alleles in rheumatoid
arthritis severity and susceptibility. Arthritis Rheum. 56: 2637–2644.
HOLOSHITZ & LING 81
11. RUIZ-MORALES, J.A., G. VARGAS-ALARCON, P.O. FLORES-VILLANUEVA, et al.
2004. HLA-DRB1 alleles encoding the “shared epitope” are associated with
susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles
encoding an aspartic acid at position 70 of the -chain are protective in Mexican
mestizos. Hum. Immunol. 65: 262–269.
12. LA CAVA, A., J.L. NELSON, W.E. OLLIER, et al.1997. Genetic bias in immune re-
sponses to a cassette shared by different microorganisms in patients with rheuma-
toid arthritis. J. Clin. Invest. 100: 658–663.
13. BHAYANI, H.R. & S.M. HEDRICK. 1991. The role of polymorphic amino acids of
the MHC molecule in the selection of the T cell repertoire. J. Immunol. 146:
1093–1098.
14. WEYAND, C.M., N.N. HUNDER, K.C. HICOK, et al. 1994. HLA-DRB1 alleles in
polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis
Rheum. 37: 514.
15. DOHERTY, D.G., P.T. DONALDSON, J.A. UNDERHILL, et al. 1994. Allelic sequence
variation in the HLA class II genes and proteins in patients with autoimmune
hepatitis. Hepatology 19: 609–615.
16. KORENDOWYCH, E., J. DIXEY, B. COX, et al. 2003. The influence of the HLA-DRB1
rheumatoid arthritis shared epitope on the clinical characteristics and radiological
outcome of psoriatic arthritis. J. Rheumatol. 30: 96–101.
17. DORAK, M.T., H.K. MACHULLA, M. HENTSCHEL, et al. 1996. Influence of the major
histocompatibility complex on age at onset of chronic lymphoid leukaemia. Int.
J. Cancer 65: 134–139.
18. OLLIER, W.E., L.J. KENNEDY, W. THOMSON, et al. 2001. Dog MHC alleles containing
the human RA shared epitope confer susceptibility to canine rheumatoid arthritis.
Immunogenetics 53: 669–673.
19. ROSLONIEC, E.F., D.D. BRAND, L.K. MYERS, et al. 1997. An HLA-DR1 transgene
confers susceptibility to collagen-induced arthritis elicited with human type II
collagen. J. Exp. Med. 185: 1113–1122.
20. FORSTHUBER, T.G., C.L. SHIVE, W. WIENHOLD, et al. 2001. T cell epitopes of hu-
man myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1∗0401)
transgenic mice are encephalitogenic and are presented by human B cells. J. Im-
munol. 167: 7119–7125.
21. GONZALEZ-GAY, M.A., C. GARCIA-PORRUA & A.H. HAJEER. 2002. Influence of
human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid
arthritis. Semin. Arthritis Rheum. 31: 355–360.
22. AHO, K., K. MARKKU, J. TUOMINEN & J. KAPRIO. 1986. Occurrence of rheuma-
toid arthritis in a nationwide series of twins. J. Rheumatol. 13: 899–
902.
23. SILMAN, A.J., A. MACGREGOR, W. THOMSON, et al. 1993. Twin concordance rates
for rheumatoid arthritis: results of a nationwide study. Br. J. Rheumatol. 32:
903–907.
24. JAWAHEER, D., W. THOMSON, A.J. MACGREGOR, et al. 1994. “Homozygosity”
for the HLA-DR shared epitope contributes the highest risk for rheuma-
toid arthritis concordance in identical twins. Arthritis Rheum. 37: 681–
686.
25. HAJEER, H., J. WORTHINGTON, A.J. SILMAN & W.E.R. OLLIER. 1996. Association
of tumor necrosis factor microsatellite polymorphism with HLA-DRB1∗04-
bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum. 39: 1109–
1114.
82 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
26. JARVINEN, P & K. AHO. 1994. Twin studies in rheumatic diseases. Semin. Arthritis
Rheum. 24: 19–28.
27. UEDA, M., S. MASHIBA & K. UCHIDA. 2002. Evaluation of oxidized -1-antitrypsin
in blood as an oxidative stress marker using anti-oxidative a1-AT monoclonal
antibody. Clin. Chim. Acta 317: 125–131.
28. SCHONLAND, S.O., C. LOPEZ, T. WIDMANN, et al. 2003. Premature telom-
eric loss in rheumatoid arthritis is genetically determined and involves both
myeloid and lymphoid cell lineages. Proc. Natl. Acad. Sci. USA 100: 13471–
13476.
29. BASHIR, S., G. HARRIS, M.A. DENMAN, et al. 1993. Oxidative DNA damage and cel-
lular sensitivity to oxidative stress in human autoimmune diseases. Ann. Rheum.
Dis. 52: 659–666.
30. LEE, S.H. et al. 2003. Microsatellite instability and suppressed DNA repair enzyme
expression in rheumatoid arthritis. J. Immunol. 170: 2214–2220.
31. GORONZY, J.J. & C.M. WEYAND. 2005. Rheumatoid arthritis. Immunol. Rev. 204:
55–73.
32. HITCHON, C.A. & H.S. EL-GABALAWY. 2004. Oxidation in rheumatoid arthritis.
Arthritis Res. Ther. 6: 265–278.
33. DONOHUE, J.F. 2006. Ageing, smoking and oxidative stress. Thorax 61: 461–462.
34. PADYUKOV, L., C. SILVA, P. STOLT, et al. 2004. A gene-environment interaction
between smoking and shared epitope genes in HLA-DR provides a high risk of
seropositive rheumatoid arthritis. Arthritis Rheum. 50: 3085–3092.
35. LING, S., A. LAI, O. BORSCHUKOVA, et al. 2006. Activation of nitric oxide signaling
by the rheumatoid arthritis shared epitope. Arthritis Rheum. 54: 3423–3432.
36. YKI-JARVINEN, H., R. BERGHOLM & M. LEIRISALO-REPO. 2003. Increased inflam-
matory activity parallels increased basal nitric oxide production and blunted
response to nitric oxide in vivo in rheumatoid arthritis. Ann. Rheum. Dis. 62:
630–634.
37. WANG, B., L. MA, X. TAO & P.E. LIPSKY. 2004. Triptolide, an active component
of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production
of nitric oxide by decreasing inducible nitric oxide synthase gene transcription.
Arthritis Rheum. 50: 2995–2303.
38. GRANT, D.D., R. GOLDSTEIN, J. KARSH & H.C. BIRNBOIM. 2001. Nitric oxide donors
induce large-scale deletion mutations in human lymphoblastoid cells: implica-
tions for mutations in T-lymphocytes from arthritis patients. Environ. Mol. Mu-
tagen. 38: 261–267.
39. TAMIR, S., T. DEROJAS-WALKER, A. GAL, et al. 1995. Nitric oxide production in
relation to spontaneous B-cell lymphoma and myositis in SJL mice. Cancer Res.
55: 4391–4397.
40. COMPTON, S.A., L.W. ELMORE, K. HAYDU, et al. 2006. Induction of nitric oxide
synthase-dependent telomere shortening after functional inhibition of Hsp90 in
human tumor cells. Mol. Cell. Biol. 26: 1452–1462.
41. CANNONS, J.L., J. KARSH, H.C. BIRNBOIM & R. GOLDSTEIN R. 1998. HPRT- mutant
T cells in the peripheral blood and synovial tissue of patients with rheumatoid
arthritis. Arthritis Rheum. 41: 1772–1782.
42. BRONTE, V. et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in
tumor-bearing mice. J. Immunol. 170: 270–278.
43. HEGARDT, P., B. WIDEGREN & H.-O. SJOGREN. 2000. Nitric-oxide-dependent sys-
temic immunosuppression in animals with progressively growing malignant
gliomas. Cell. Immunol. 200: 116–127.
HOLOSHITZ & LING 83
44. POPE, R.M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev.
Immunol. 2: 527–535.
45. MOUNTZ, J.D., H.-C. HSU, Y. MATSUKI & H.-G. ZHANG. 2001. Apoptosis and
rheumatoid arthritis: past, present and future directions. Curr. Rheum. Rep. 3:
70–78.
46. BROWN, J.H., T.S. JARDETZKY, J.C. GORGA, et al. 1993. Three-dimensional structure
of the human class II histocompatibility antigen HLA-DR1. Nature 364: 33–39.
47. GLEIMER, M. & P. PARHAM. 2003. Stress management: MHC class I and class I-like
molecules as reporters of cellular stress. Immunity 19: 469–477.
48. BROOKS, A.G., J.C. BOYINGTON & P.D. SUN. 2000. Natural killer cell recognition
of HLA class I molecules. Rev. Immunogenet. 2: 433–448.
49. BENNETT, M.J., J.A. LEBRON & P.J. BJORKMAN. 2000. Crystal structure of the heredi-
tary haemochromatosis protein HFE complexed with transferrin receptor. Nature
403: 46–53.
50. LOCONTO, J., F. PAPES, E. CHANG, et al. 2003. Functional expression of murine
V2R pheromone receptors involves selective association with the M10 and M1
families of MHC class Ib molecules. Cell 112: 607–618.
51. BOGDAN, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2: 907–
916.
52. FULOP, T., JR., A. LARBI, G. DUPUIS & G. PAWELEC. 2003. Ageing, autoimmunity
and arthritis: Perturbations of TCR signal transduction pathways with ageing—a
biochemical paradigm for the ageing immune system. Arthritis Res. Ther. 5:
290–302.
53. WU, Y., J. ZHENG, J. LINDEN & J. HOLOSHITZ. 2004. Genoprotective pathways.
Part I. Extracellular signaling through Gs protein-coupled adenosine receptors
prevents oxidative DNA damage. Mutat. Res. 546: 93–102.
